Last reviewed · How we verify
Farletuzumab, Carboplatin, and PLD
Farletuzumab, Carboplatin, and PLD is a Small molecule drug developed by Morphotek. It is currently in Phase 1 development. Also known as: Farletuzumab (MORAb-003), Carboplatin, PLD.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Farletuzumab, Carboplatin, and PLD |
|---|---|
| Also known as | Farletuzumab (MORAb-003), Carboplatin, PLD |
| Sponsor | Morphotek |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer (PHASE2)
- Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Farletuzumab, Carboplatin, and PLD CI brief — competitive landscape report
- Farletuzumab, Carboplatin, and PLD updates RSS · CI watch RSS
- Morphotek portfolio CI
Frequently asked questions about Farletuzumab, Carboplatin, and PLD
What is Farletuzumab, Carboplatin, and PLD?
Who makes Farletuzumab, Carboplatin, and PLD?
Is Farletuzumab, Carboplatin, and PLD also known as anything else?
What development phase is Farletuzumab, Carboplatin, and PLD in?
Related
- Manufacturer: Morphotek — full pipeline
- Also known as: Farletuzumab (MORAb-003), Carboplatin, PLD
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing